
FTH Stock Forecast & Price Target
FTH Analyst Ratings
Bulls say
Faeth Therapeutics is a clinical-stage biotechnology company with a strong focus on improving outcomes for cancer patients, particularly in the areas of breast and endometrial cancer. The company's leading drug candidate, Piktor, has shown promising results in preclinical and early clinical studies and has initiated coverage with a Buy rating and a $70 price target. Ongoing trials and the potential for improving tolerability and efficacy suggest potential for continued success.
Bears say
Faeth Therapeutics is facing several key challenges in the development and potential success of their drug PIKTOR. These challenges include finding a tolerable dosage, competition from other drugs, and the risks associated with a single-arm Phase 2 design. Additionally, the estimated equity value for the company is quite high, which may not be sustainable if the drug does not meet expectations or faces major setbacks in its development.
This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FTH Analyst Forecast & Price Prediction
Start investing in FTH
Order type
Buy in
Order amount
Est. shares
0 shares